openPR Logo
Press release

Doxorubicin Market to Witness an Outstanding Growth by 2024

Doxorubicin Market to Witness an Outstanding Growth by 2024

Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). Anthracycline especially doxorubicin has been the mainstay of cancer treatment since many years. Doxorubicin also known as doxorubicin hydrochloride is an antibiotic belonging to class of medication known as anthracycline antibiotics, and is the first liposomal encapsulated anticancer drug to receive clinical approval and is used in the treatment of several types of carcinomas. Doxorubicin is produced by the soil fungus belonging to genus Streptomyces. The drug is used in combination with other drugs to treat cancers such as, breast, lung, bladder, stomach, ovarian, neuroblastoma, Hodgkin and non-Hodgkin lymphomas, and certain types of leukemia’s. It is less commonly used in treatment of squamous cell carcinomas of head and neck, cervix and vagina, carcinomas of testes and prostate. The drug kills the cancerous cells in several ways including intercalation between DNA pairs thereby preventing replication of cancer cells, DNA strand breakage and inhibition with enzyme topoisomerase II. Doxorubicin is marketed either in the powdered or in solution form and is administered intravenously every 21 to 28 days. However, the treatment depends upon the type of cancer being treated, the types of other drugs that are taken during the treatment and how well the body response to the medicine. The drug is sometimes given as a continuous infusion wherein the drug is infused slowly into the patient’s body.

Global doxorubicin market is expected to witness upsurge in its revenue over the forecast period attributed to growing prevalence of cancer worldwide. WHO estimates that cancer prevalence is expected to increase at an estimated rate of 50% by 2050. Furthermore, increasing use of drug in the treatment of ovary cancer is further expected to increase the sales of the doxorubicin over the forecast period. The drug is also known to have high treatment efficacy in patients with AIDS-related Kaposi’s sarcoma after failure of prior systemic chemotherapy. However, conventional doxorubicin treatment imposes several side effects such as nausea and vomiting that may last 24–48 hours after treatment, hair loss, myelosuppression, loss of appetite, diarrhea, localized swelling etc. Therefore, the need for development of doxorubicin with liposomal formulation arose improving therapeutic index of conventional doxorubicin. This strategy resulted in preferential accumulation of doxorubicin within the cancerous cell in order to maximize the drug efficacy and minimize toxicity, thus fueling the doxorubicin market growth in the near future.

A sample of this report is available upon request @ https://www.persistencemarketresearch.com/samples/12637

One of the most common and prevailing side effect of doxorubicin is cardiomyopathy with an estimated incidence of 4% at a dose of 500–550 mg/m², subsequently leading to congestive heart failure. The rate of cardiomyopathy reaches to 36% when the dose exceeds 600 mg/m². This may lead to introduction of drugs with lesser side effects replacing the doxorubicin in the future. However, ongoing shortages of the drug has also affected the revenues of the doxorubicin market contently.

The global market for Doxorubicin is segmented on basis of formulation, cancer type, distribution channel and geography:

Segmentation by Formulation
Lyophilized Doxorubicin Powder
Doxorubicin Solution
Segmentation by Cancer Type
Breast Cancer
Prostate Cancer
Ovary Cancer
Lung Cancer
Bladder Cancer
Stomach Cancer
Leukemia
Others
Segmentation by Distribution Channel
Hospitals Pharmacies
Retail Pharmacies
E-Commerce
Increasing prevalence of several cancer types have resulted in increasing usage of doxorubicin in clinical practice thus driving the revenues for the same. By formulation, the global market for doxorubicin has been classified into, lyophilized doxorubicin powder and doxorubicin solution

By cancer type, the global doxorubicin market is segmented into, breast cancer, prostate cancer, ovary cancer, lung cancer, bladder cancer, stomach cancer, leukemia and others. Breast cancer and prostate cancer segments are expected to account for maximum revenue share in global doxorubicin market over the forecasted period.

On the basis of distribution channel, the global doxorubicin market is segmented into, hospital pharmacies, retail pharmacies and e-commerce.

On the basis of regional presence, global doxorubicin market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America will continue to dominate the global doxorubicin market attributed to growing number of cancer epidemiology in the region. Furthermore, doxorubicin shortages in the past few years due to manufacturing issues have resulted in entry of increasing number of players in the market. This has substantially improved the revenue of global doxorubicin market in the near future. Asia Pacific is expected to be the fastest growing region in global doxorubicin market attributed to increasing prevalence of breast and lung cancer.

To view TOC of this report is available upon request @ https://www.persistencemarketresearch.com/toc/12637

Some of the major players operating in global doxorubicin market are Pfizer Inc., Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Meiji Seika Pharma Co., Ltd., Teva Pharmaceutical Industries Ltd., MicroBiopharm Japan Co., Ltd., and Synbias Pharma. Companies are involved in collaboration agreements for R&D in order to exploit maximum potential.

About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Doxorubicin Market to Witness an Outstanding Growth by 2024 here

News-ID: 713409 • Views:

More Releases from Persistence Market Research 

Intra Aortic Balloon Pump Market Expected to Behold a CAGR of 2.7% through 2027
Intra Aortic Balloon Pump Market Expected to Behold a CAGR of 2.7% through 2027
Growing prevalence of lethal diseases, such as cardiac arrest and heart failure due to changing lifestyle and eating habits is leading to increasing cardiac surgeries and procedures worldwide. Of late, intra-aortic balloon pump has emerged as a cutting-edge product in cardiac management and care. It is basically a polyethylene balloon mounted on a catheter that assists heart during both its rest phase and work phase. However, there have been occasions
Pediatric Hearing Aids Market Size By 2025 | Top Key Players are Sonova, William Demant, Sivantos, GN Store Nord (ReSound), Starkey Technologies, and Widex
Pediatric Hearing Aids Market Size By 2025 | Top Key Players are Sonova, William …
Persistence Market Research (PMR) has recently published a new research report titled, “Pediatric Hearing Aids Market: Global Industry Analysis (2012 – 2016) and Forecast (2017 – 2025).” Hearing aids can help improve the hearing and speech of children with sensorineural hearing loss (hearing loss in the inner ear due to damaged hearing nerve). Sensorineural hearing loss can be caused by noise, injury, infection, certain medications, birth defects, tumors, and problems
Intra Operative Imaging Market Growth By 2024 | Top Key Players are IMRIS Inc., NeuroLogica Corp., GE Healthcare, and Medtronic Plc.
Intra Operative Imaging Market Growth By 2024 | Top Key Players are IMRIS Inc., …
Persistence Market Research has recently published its report on the global market for intraoperative imaging, excerpts from which predict the market to be presently valued at US$ 513.9 million. According to the report, the demand for intraoperative imaging will keep surging on the grounds of increasing adoption of minimally-invasive surgeries and remarkable progress witnessed in the field of diagnostic imaging for neurosurgeries. The world’s leading medical research institutes are also
Explosive Detection Equipment Market to Reflect Impressive Growth Rate During 2017-2025
Explosive Detection Equipment Market to Reflect Impressive Growth Rate During 20 …
Global Explosive Detection Equipment Market: Introduction With the growing threat of terrorism across the globe, explosive detection equipment is a necessity of today’s world. The equipment used for explosive detection prevents the shipping of illegal materials, such as narcotics and small arms. Common explosives are made of organic as well as inorganic nitrogen and nitrate compounds, such as ammonium nitrate in fuel oil (ANFO) and triacetone triperoxide (TATP). There are several

All 5 Releases


More Releases for Doxorubicin

Global Doxorubicin Market Insights, Forecast
Doxorubicin is a kind of antitumor antibiotics, can inhibit the synthesis of RNA and DNA, RNA in the strongest inhibitory effect. Doxorubicin has an effect on a wide variety of tumor, belongs to the cycle non-specific drug, have all sorts of growth cycle of tumor cells to kill.it's given by injection into a vein. The global Doxorubicin market is valued at 910 million US$ in 2018 and will reach 1410
Doxorubicin Global Industry Report - History, Present and Future 2019
The global market size of Doxorubicin is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023. There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment. For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from
Doxorubicin Market Report Explored in Latest Research 2025
Doxorubicin is the generic drug name for anti-cancer chemotherapy drug Adriamycin and Rubex. Doxorubicin is an anthracycline antibiotic and belongs to the group of anti-cancer medication known as antineoplastic and is made from the natural product produced by bacterium Streptomyces peucetius var. caesius. Request Brochure- https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26138 It is used for the treatment of different types of cancer including breast, stomach, ovary, bone, testicles, bladder, lung, soft tissue, osteogenic sarcoma, Wilms’ tumor, and Hodgkin’s
Doxorubicin Market to Reflect Steady Growth Rate by 2024
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). Anthracycline especially doxorubicin has been the mainstay of cancer treatment since many years. Doxorubicin also known as doxorubicin hydrochloride is an antibiotic belonging to class of medication known as anthracycline antibiotics, and is the first liposomal encapsulated anticancer drug to receive clinical approval and is used in the
Doxorubicin Market Rugged Expansion Foreseen by 2024
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). Anthracycline especially doxorubicin has been the mainstay of cancer treatment since many years. Doxorubicin also known as doxorubicin hydrochloride is an antibiotic belonging to class of medication known as anthracycline antibiotics, and is the first liposomal encapsulated anticancer drug to receive clinical approval and is used in the
Global Doxorubicin Market 2017 By Key Manufacturers: Teva
The motive of this strategic research report entitled "Global Doxorubicin Market 2017" is to provide company officials, industry investors, and industry members with consequential insights to enable them make reliable strategic decisions regarding the opportunities in the global Doxorubicin market. Key Notes On Doxorubicin Market: "Global Doxorubicin Market 2017 "offers crucial insights into the global Doxorubicin market along with the market size and estimates for the duration 2017 to 2023. This industry report